The Role of CDK 4/6 Inhibitors in Breast Cancer Treatment. - Wikidata - wikimedia - TriplyDB

The Role of CDK 4/6 Inhibitors in Breast Cancer Treatment.

The Role of CDK 4/6 Inhibitors in Breast Cancer Treatment.

http://www.wikidata.org/entity/Q37124719

about

Altered Expression of Cell Cycle Regulators in Adult T-Cell Leukemia/ Lymphoma Patients.

P2860

Q42694476-3A29244A-387B-476F-9858-AE21994CDEEE

P2860

The Role of CDK 4/6 Inhibitors in Breast Cancer Treatment.

http://www.wikidata.org/entity/Q37124719

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 22 June 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

The Role of CDK 4/6 Inhibitors in Breast Cancer Treatment.

@en

The Role of CDK 4/6 Inhibitors in Breast Cancer Treatment.

@nl

type

label

The Role of CDK 4/6 Inhibitors in Breast Cancer Treatment.

@en

The Role of CDK 4/6 Inhibitors in Breast Cancer Treatment.

@nl

prefLabel

The Role of CDK 4/6 Inhibitors in Breast Cancer Treatment.

@en

The Role of CDK 4/6 Inhibitors in Breast Cancer Treatment.

@nl

P1433

Q37124719-962205FB-A149-42D4-A73C-FB5F9831B8D3

P1476

Q37124719-F1D188DF-9F27-4A77-B7C7-A018F12C835C

P2093

Q37124719-65051849-DE6D-4F75-8F27-A8FA421DC177

Q37124719-C633BB74-D47B-4CF7-B164-CD47F80EA432

P2860

Q37124719-23389673-236E-4CFA-BBD8-79796E80D4E4

Q37124719-304521D6-B757-4508-B5AF-231D09A4C429

Q37124719-3124D5D0-04F5-4F2C-8E40-FE7B7E906E43

Q37124719-77BFB315-93E5-4FBF-9500-A51FCADB3947

Q37124719-A04DA7B6-EC63-4470-A492-2DAE733D968F

Q37124719-E189A432-F84E-482C-8204-AC6405B14270

P304

Q37124719-581B16B7-9AE4-468E-B54A-D9FDCD8F0612

P31

Q37124719-3FCC9F31-C717-4948-AB86-FE3AF6303015

Q37124719-c9d30e10-76fc-4a79-a1c2-87105b1dbdb8

P356

Q37124719-5B2D6964-9C92-472E-A70E-147A5B199982

P433

Q37124719-F04FD7F0-1507-4DEF-931D-B2238F9C972E

P478

Q37124719-B2A1DBC2-AF40-4F07-8F18-040C93F0E2CF

P577

Q37124719-FA9DBAF9-6F48-4967-AEEE-87F00C49ACB3

P698

Q37124719-E6AD221A-87EC-4EBE-BFD2-B58084F3A655

P932

Q37124719-18FB7F6E-E34B-47F6-81DF-6D5C8B996E85

P356

P1433

P1476

The Role of CDK 4/6 Inhibitors in Breast Cancer Treatment.

@en

P2093

Isabell Witzel

http://www.w3.org/2001/XMLSchema#string

Volkmar Müller

http://www.w3.org/2001/XMLSchema#string

P2860

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

Aromatase inhibitors in breast cancer.

The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer.

Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial.

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind

Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.

P304

165-166

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000447479

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2016-06-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27493614

http://www.w3.org/2001/XMLSchema#string

P932

4960363

http://www.w3.org/2001/XMLSchema#string